Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 37504327)

  • 1. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
    Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
    Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
    Kazandjian D; Kowalski A; Landgren O
    Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
    Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ
    Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
    Holstein SA; Grant SJ; Wildes TM
    J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
    Martino M; Paviglianiti A
    Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
    [No Abstract]   [Full Text] [Related]  

  • 8. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
    Kegyes D; Constantinescu C; Vrancken L; Rasche L; Gregoire C; Tigu B; Gulei D; Dima D; Tanase A; Einsele H; Ciurea S; Tomuleasa C; Caers J
    J Hematol Oncol; 2022 Jun; 15(1):78. PubMed ID: 35672793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
    Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
    Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
    Sunder-Plassmann V; Aksoy O; Lind J; Pecherstorfer M; Vallet S; Podar K
    Expert Opin Pharmacother; 2022 Aug; 23(12):1425-1444. PubMed ID: 35829636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
    Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
    Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
    Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
    Alqazaqi R; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Tricot G; van Rhee F; Al Hadidi S
    JAMA Netw Open; 2022 Aug; 5(8):e2228877. PubMed ID: 36018590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
    Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.
    Susanibar Adaniya SP; Cohen AD; Garfall AL
    Am J Hematol; 2019 May; 94(S1):S28-S33. PubMed ID: 30730071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Antibodies in the Treatment of Multiple Myeloma.
    Zhou X; Xiao X; Kortuem KM; Einsele H
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Off-the-shelf" immunotherapies for multiple myeloma.
    Mohammed T; Mailankody S
    Semin Oncol; 2022 Feb; 49(1):60-68. PubMed ID: 35123801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.